CABS Science Workshop: Chemistry Innovations in Drug Discover
Date: April 23, 2016 @ 1:00 pm – @ 5:00 pm
Location: Hanqi office, 1633 Bayshore Hwy Ste 280, Burlingame, CA 94010
Free registration for everyone!
List of speakers
Dr. YK Zhang, Discovery of Benzoxaborole Antimalarial Agents, Research Leader of Anacor
Kerydin® (Tavaborole), approved by the FDA in July 2014 for the topical treatment of onycomycosis of the toenails, is one of the bioactive clinical compounds YK Zhang and his colleagues discovered for Anacor Pharmaceuticals, Inc., Palo Alto, California. YK has worked in many biotech companies in the Bay Area, and has conducted research for Anacor since 2003. His experience includes leading medicinal chemistry teams for HCV, malaria, and three animal health discovery programs, managing chemistry outsourcing with international CROs and integrating medicinal chemistry research activities for discovery programs. In the course of his research, he has contributed to 54 patents and applications, 66 peer-reviewed scientific research articles and presented at 46 conferences.
Dr. Henry Johnson, Targeting the Immunoproteasome, Principal Scientist of Kezar Biotheapeutics
Henry W. B. Johnson is a Principal Scientist at Kezar Life Sciences, a startup focused on developing innovative new therapies targeting protein homeostasis. Prior to joining Kezar he was a senior member of the medicinal chemistry team at Onyx Pharmaceuticals and Exelixis. Over the course of his career he has led or been a primary contributor on many successful project teams including the development of five small molecules which entered the clinic. He obtained his PhD in the laboratory of Jon Rainier at the University of Utah where his work was focused in the area of natural product synthesis and methodology. He earned his B.S. in biochemistry from Cal Poly, San Luis Obispo. Dr. Johnson is an author on more than 40 scientific publications and patents.
Dr. Leping Li, Expanding the HCV Infection Treatment Options through Chemistry, VP of Assembly Biosciences
Leping Li, PhD, has more than 20 years of experience in drug discovery and early development, leading project teams and advancing multiple programs from early lead identification to advanced clinical development in infectious diseases, cancer and metabolic disorders. Leping joined Assembly Biosciences as Vice President, Discovery this year. Prior to this position, he was with Presidio Pharmaceuticals, where he was Vice President of Chemistry and inventor of the HCV NS5A inhibitor ravidasvir. Previously, he was Scientific Director in Medicinal Chemistry at Amgen, where he received the 2004 Robert A. Swanson Distinguished Employee Award. Before Amgen (and Tulrik), Dr. Li served as a Research Investigator at Abbott Laboratories. Dr. Li obtained a BS degree from Shandong University in China. He earned a PhD in organic chemistry at Rice University and conducted postdoctoral research at Stanford University.
I wish to express my deep gratitude to speakers’ kind support and time to prepare the seminar. The presentation will provide great benefit to the CABS community. We will have a great event!
.